Brief: Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323
09/04/2026 11:53
April 9 (Reuters) - Duality Biotherapeutics Inc 9606.HK: NMPA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 IN HER2-POSITIVE BREAST CANCER Further company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Duality Biotherapeutics
See all newsDuality Biotherapeutics rises most in near six weeks on Roche's Genentech tie-up
Brief: Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech
Brief: Duality Biotherapeutics Obtains Acceptance From Shanghai Securities Regulatory Bureau For Counselling On Proposed RMB Share Listing
Brief: Duality Biotherapeutics Announces Share Repurchase Plan Of Up To $40 Million
Brief: Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board